| Period Ending: | 2024 12-31 |
2023 12-31 |
2022 12-31 |
2021 12-31 |
2020 12-31 |
2019 12-31 |
2018 12-31 |
2016 12-31 |
2014 12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total |
1234
|
||||||||
| YUPELRI Monotherapy |
1234
|
||||||||
| YUPELRI Monotherapy (%) |
1234
|
||||||||
| Collaboration revenue |
1234
|
||||||||
| Collaboration revenue (%) |
1234
|
||||||||
| Licensing revenue |
1234
|
||||||||
| Licensing revenue (%) |
1234
|
||||||||
| Viatris collaboration agreement |
1234
|
||||||||
| Viatris collaboration agreement (%) |
1234
|
||||||||
| Collaborative revenue |
1234
|
||||||||
| Collaborative revenue (%) |
1234
|
||||||||
| Collaborative Arrangement Revenue |
1234
|
||||||||
| Collaborative Arrangement Revenue (%) |
1234
|
||||||||
| Co Promote Agreement |
1234
|
||||||||
| Co Promote Agreement (%) |
1234
|
||||||||
| License |
1234
|
||||||||
| License (%) |
1234
|
||||||||
| Product |
1234
|
||||||||
| Product (%) |
1234
|
||||||||
| Ns5a Inhibitor |
1234
|
||||||||
| Ns5a Inhibitor (%) |
1234
|
||||||||
| V I B A T I V Product |
1234
|
||||||||
| V I B A T I V Product (%) |
1234
|
||||||||
